AIMM Therapeutics
AIMM therapeutics B.V. was established in 2004 with the goal to develop therapeutic and prophylactic human monoclonal antibodies. AIMM’s capitalizes on a breakthrough proprietary technology to isolate human monoclonal antibodies for prevention and treatment of infectious diseases, inflammatory diseases and cancer.